Transplantation-associated microangiopathy (TAM) or renal insufficiency (RI) after allogeneic hematopoietic stem cell transplantation is associated with a high mortality. As calcineurin inhibitors (CI) may contribute to TAM or RI, we evaluated the efficacy of replacing CI by daclizumab in patients with graft-versus-host disease (GVHD). Thirteen patients with GVHD-associated TAM and five patients with RI were treated with daclizumab 1 mg/kg intravenous (i.v.)/week, discontinuation of the CI and continuation of the remaining GVHD treatment. All patients had acute GVHD (steroid-sensitive (n ¼ 4), steroid-refractory (n ¼ 10)) or chronic GVHD (n ¼ 4) and were treated with CI before the start of daclizumab. Nine of 13 patients with TAM treated with daclizumab and discontinuation of CI achieved complete remission of TAM, two had stable disease, and one patient did not respond. Patients receiving daclizumab for RI without TAM showed stabilization (2/5) or improvement (3/5) of renal function. Four of 14 patients with acute GVHD achieved CR, two partial remission, eight patients did not respond and 11/14 died at a median of 39 days after start of the daclizumab. Our data demonstrate that replacement of CI by daclizumab can improve TAM and RI. However, mortality remains high in patients with acute GVHD.
Introduction
Transplantation-associated microangiopathy (TAM) or renal insufficiency (RI) in combination with acute or chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT) occur with a frequency of 4-9% after alloHSCT and are associated with a high morbidity and mortality.
1 TAM after alloHSCT is regarded as the consequence of pronounced endothelial damage caused by the conditioning regimen, subsequent enhancement of the damage by infectious complications through lipopolysaccharides and activation of residual host cells, toxic side effects of drugs administered for immunosuppression (calcineurin inhibitors, sirolimus) and GVHD via infiltration of activated donor cells as well as cell-cell contact cytotoxicity via FasL and membrane tumor necrosis factor. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The specific pathogenesis in TAM with focus on endothelial toxicity explains the different pattern of von Willebrand factor cleaving protease (vWF-cleaving protease) activity, which is normal in most cases, whereas classical thrombotic thrombocytopenic purpura (TTP) is associated with a significant decrease of vWF-cleaving protease activity. 2, 12, 13 The specific pathogenesis of TAM is reflected by clinical risk factors for TAM, which are equally risk factors for increased endothelial toxicity: use of total body irradiation, calcineurin inhibitors in prophylaxis of acute GVHD, sirolimus in treatment of acute GVHD, use of unrelated donors, as well as acute and chronic GVHD, and advanced patient age. [13] [14] [15] [16] [17] The main clinical features of TAM are hemolysis and thrombocytopenia. Up to 50% of the patients may develop additional neurological symptoms as well as RI. Hemolysis is characterized by the absence of antierythrocytic antibodies and the detection of schistocytes in the blood smear as well as a normal vWV-cleaving protease activity. 1, 2, 18, 19 As treatment options are limited in TAM, its mortality remains high. 1, 15, 20, 21 Potential treatment options are the use of defibrotide and withdrawal of the calcineurin inhibitor. 1, [22] [23] [24] [25] [26] Although plasma exchange is the treatment of choice in classical TTP, reports on the efficacy of plasma exchange in TAM suggest at best limited activity in selected patients, whereas the majority does not respond. 1, 20, [27] [28] [29] The most likely explanation is that the vWF-cleaving protease is not involved in TAM. 2 As calcineurin inhibitors are part of the pathogenesis of TAM and are associated with RI, withdrawal may be desirable. [30] [31] [32] However, calcineurin inhibitors are a central part of GVHD prophylaxis and treatment and the latter is associated with TAM. Therefore, the positive effect of withdrawal of the calcineurin inhibitor is potentially offset by the subsequent progression of GVHD. The same problem applies to treatment of isolated RI in patients with GVHD, which may develop as a result of administration of nephrotoxic drugs (e.g. calcineurin inhibitors, amphotericin B, aminoglycosides) as well as from severe infectious complications with septic shock. [30] [31] [32] [33] Furthermore, the high drug levels of calcineurin inhibitors used for long-term immunosuppression in the presence of chronic GVHD frequently cause impairment of renal function, which may lead to subsequent RI. 30, 32, 34 Therefore, withdrawal of the calcineurin inhibitor requires institution of an alternative immunosuppressive drug, which should not be associated with endothelial or renal toxicity. Daclizumab is a humanized antibody against the Tac subunit of the interleukin (IL)-2 receptor and has been successfully used in treatment of acute GVHD after alloHSCT as well as in RI after renal or liver transplantation. [35] [36] [37] [38] [39] [40] In contrast to calcineurin inhibitors, daclizumab specifically blocks the effect of IL-2 on the receptor level and has no direct cytotoxic effect on lymphocytes and endothelial cells.
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Here, we report our experience in treatment of TAM (n ¼ 13) and RI (n ¼ 5) with daclizumab as a substitute for the calcineurin inhibitor in patients with GVHD.
Patients and methods
Thirteen patients developing TAM in association with GVHD after allogeneic stem cell transplantation between March 2001 and March 2005 at the Department of Haematology and Oncology of the University of Rostock (HRO) (n ¼ 11), the Department of Haematology and Oncology at the University Hospital of Regensburg (REG) (n ¼ 1) and the Department of Internal Medicine III, Campus Benjamin Franklin, Charite´-University Hospital Berlin (BER) (n ¼ 1) were included for evaluation. Four patients with TAM were treated on a multicenter protocol, which was reviewed and approved by an Institutional Review Board including written informed consent. The remaining nine patients with TAM were included in the analysis retrospectively. The median time from transplant to the initiation of daclizumab therapy was 120 days . The diagnosis of TAM was established using standard criteria, that is the presence of antibody-negative hemolysis in combination with schistocytes in the blood smear, thrombocytopenia, exclusion of disseminated intravascular coagulation as well as the need for red cell transfusions. 1, 19 Patient characteristics are summarized in Table 1 . In addition, five patients developing isolated RI during calcineurin inhibitor-containing treatment of acute GVHD (n ¼ 2) or extensive chronic GVHD (n ¼ 3) were treated with replacement of the calcineurin inhibitor by daclizumab ( Table 2 ). The need for withdrawal of the calcineurin inhibitor owing to RI was defined as progressively reduced renal function (creatinine clearance below 60 ml/min) despite withdrawal of all concomitant nephrotoxic drugs and dose reduction of the calcineurin inhibitor to the lowest possible therapeutic level (tacrolimus o5 ng/ml, cyclosporin o150 ng/ml). Three patients had a prior history of chronic RI unrelated to the use of calcineurin inhibitors (multiple myeloma n ¼ 1, history of renal failure due to local tumor progress n ¼ 1, renal amyloidosis n ¼ 1).
Complete remission of TAM was defined as the absence of signs of TAM (lack of signs of hemolysis). Stable TAM disease was defined by the absence of neurological abnormalities and no further impairment of renal function attributable to TAM in the presence of decreased haptoglobin and increased LDH.
TAM associated with acute GVHD was treated with daclizumab 1 mg/kg weekly intravenously (i.v.), with an initial loading dose of 2 m/kg, discontinuation of the calcineurin inhibitor (n ¼ 13) and sirolimus (n ¼ 1) and continuation of the remaining GVHD treatment (steroids Table 3) . Daclizumab taper was initiated in the presence of complete remission of TAM and GVHD by prolongation of the application interval. Defibrotide was given for ongoing TAM after withdrawal of cyclosporin in one patient at a dose of 20 mg/kg/day i.v. A second patient received defibrotide 20 mg/kg/day starting on day 41 after onset of TAM in the absence of hemolysis but ongoing thrombocytopenia and GVHD.
In patients with RI, the calcineurin inhibitor was replaced by daclizumab 1 mg/kg weekly i.v. with a subsequent extended application interval in the event of remission of GVHD. The remaining GVHD treatment consisted of steroids (n ¼ 4), sirolimus (n ¼ 2) and pentostatin (n ¼ 1) (Table 4) .
Pentostatin was administered at a dose of 4 mg/m 2 every 2nd week in patient UPN 362HRO and UPN 425HRO. Patient UPN 426HRO received two doses of pentostatin 2 mg/m 2 weekly for treatment of steroid-refractory GVHD in the presence of impaired renal function. Patient UPN 523HRO received pentostatin 0.75 mg/m 2 /day for 3 consecutive days for treatment of steroid-refractory GVHD in the presence of RI.
All patients received antifungal prophylaxis/treatment consisting of an agent active in infections with the Aspergillus species (itraconazole, amphothericin B, caspofungin or voriconazole) and were monitored for invasive aspergillosis by PCR and serological antigen screening (galactomanan test). In addition, all patients were monitored weekly for CMV reactivation (early antigen pp65) and pre-emptive treatment with ganciclovir was initiated in the event of CMV reactivation. If clinically indicated (thrombocytopenia and/or leukopenia), additional screening for HHV6 and parvovirus B19 by PCR was performed. Patient survival was determined using the KaplanMeier-product limit method. To compare survival of different subgroups, P-values were determined using logrank tests. Calculations were performed using the SPSS software.
Results
Response of TAM/RI Nine of 13 patients receiving daclizumab achieved complete remission of TAM whereas two patients showed stable disease. Two patients did not respond and progressed with TAM and GVHD (Table 3) . Patient UPN 362 achieved partial remission of TAM and GVHD after withdrawal of daclizumab and treatment with ATG. Patient UPN 362HRO had an episode of mild TAM 3 months before the onset of severe TAM treated with daclizumab, in association with acute GVHD, after donor lymphocyte infusion (DLI), which responded rapidly to ATG. Although daclizumab failed to induce remission of TAM, the latter responded again to ATG. Patient UPN 425HRO developed a second episode of TAM at day 1007 in association with chronic GVHD, which responded to increased immunosuppression and defibrotide.
Replacement of the calcineurin inhibitor by daclizumab in the presence of progressive RI resulted in stabilization in two patients and improvement of renal function in three of five patients (Table 4 ).
Response of GVHD
Five patients receiving daclizumab for treatment of TAM achieved complete remission of GVHD and two patients (Table 3) . In patients receiving daclizumab as a substitute for the calcineurin inhibitor owing to RI, three patients achieved partial remission of chronic GVHD, whereas the two patients with acute GVHD did not respond (Table 4 ).
Survival
Four of 13 patients achieving complete remission of TAM and GVHD survived with a follow-up of 266, 839, 912 and 1030 days post transplantation. One additional patient achieving complete remission of TAM and GVHD died because of relapse of Hodgkin's disease 116 days after initiation of treatment with daclizumab. Eight of 13 patients with TAM died because of infectious complications (n ¼ 6), GVHD (n ¼ 1) and multi-organ failure in association with TAM (n ¼ 1) at a median of 45 days (range 15-177 days) after initiation of treatment with daclizumab. Whereas two patients (UPN 196REG, 420BER) died because of infectious complications associated with subsequent chronic GVHD after successful treatment of acute GVHD, the remaining six patients died with symptoms of active acute GVHD. The survival in patients with either mild acute GVHD (UPN 425HRO, 196REG, 594HRO), acute GVHD grade 3 responding to steroids (UPN 364HRO) or chronic GVHD (UPN 458HRO) responding to treatment was significantly superior compared to patients with steroid-refractory GVHD (P ¼ 0.018). Both patients receiving daclizumab for treatment of RI during treatment of acute GVHD died because of preexisting infectious complications 19 and 23 days after initiation of daclizumab. Two patients receiving daclizumab for progressive RI during treatment of chronic GVHD with a calcineurin inhibitor died 479 and 172 days after the start of the daclizumab. One patient is alive with partial remission of chronic GVHD.
Infectious complications
Bacterial infections. Six patients developed bacterial infections WHO grade 3-4, which were the primary cause of death in two patients in association with refractory acute GVHD and led to admission in patient UPN 408.
Fungal infections. Four patients developed systemic infections with Candida species and four patients developed invasive aspergillosis. Two of the four patients (UPN 196REG and 420BER) developed invasive aspergillosis after completion of treatment with daclizumab in association with chronic GVHD. One additional patient (UPN 362HRO) developed invasive mucor mycosis while being treated for preexisting invasive aspergillosis with voriconazole.
Viral infections. Two patients developed CMV reactivation. One of them required prolonged treatment with foscarnet owing to primary ganciclovir resistance. One patient developed hemorragic cystitis owing to BK virus reactivation. One patient developed HHV6 reactivation, which was treated with ganciclovir.
Toxicity. Except for infectious complications, no toxic adverse effects of daclizumab and defibrotide were observed.
Discussion
The specific pathogenesis of TAM with a close association with GVHD as well as calcineurin and mTOR inhibitors (sirolimus), which are necessary for control of GVHD, provokes a challenging situation. Considering the high mortality of transplantation-associated TAM observed in the present case series as well as in other reports, effective treatment options are urgently needed.
The use of the humanized anti-CD25 antibody daclizumab which has neither an endothelial nor nephrotoxic potential, offers the possibility of replacing calcineurin inhibitors. The high response rate of TAM (9/13 patients) after withdrawal of calcineurin inhibitors and treatment with daclizumab demonstrates the efficacy of the approach with regard to control of TAM, which was superior compared to results reported using plasmapheresis. 1, 15, 20, 29, 42 However, only five of 13 patients achieved complete remission of GVHD, indicating that substitution of the calcineurin inhibitor by daclizumab alone is not sufficient treatment for GVHD in a significant proportion of patients who require additional treatment. This is even more important taking into account that long-term survival was observed only in patients achieving complete remission of both TAM and GVHD (4/13). The difference between the response of TAM compared to GVHD may be partly explained by the high rate of grade IV acute GVHD in the non-responder group, indicating that patients with severe GVHD may need more aggressive immunosuppression. Another explanation for the high response rate of TAM may have been that the majority of patients had mild to moderate TAM without renal and cerebral involvement, which has been associated with a superior survival compared to patients with severe TAM including multiorgan involvement. 43 The difference in the survival between patients with TAM in association with steroid-responsive GVHD compared to patients with TAM with steroid-refractory GVHD indicates that endothelial cells may be a target of GVHD in the latter group. Data from Biedermann et al. 44, 45 indicate that acute GVHD is associated with endothelial damage and endothelial cells may be a target for alloreactive T-cells. The high failure rate of daclizumab in patients with steroid-refractory GVHD with either TAM or RI indicates that daclizumab is not an adequate treatment for GVHD after withdrawal of the calcineurin inhibitor in this subgroup of patients and a more aggressive immunosuppressive regimen is required. This is supported by the observation of repeated response of TAM to ATG in one patient.
Although one patient achieved remission of TAM with defibrotide after failure of substitution of cyclosporin by Daclizumab in transplantation-associated microangiopathy D Wolff et al daclizumab, it is difficult to draw any conclusion from this single case with regard to the role of defibrotide. The latter has been successfully used as single agent in treatment of TTP (TAM) in a limited number of patients, and promising data on treatment of VOD, which shares some pathogenic aspects with TAM, suggest that defibrotide may be an effective treatment option in patients with TAM. [22] [23] [24] [25] 46 Nevertheless, the need for substitution of calcineurin inhibitors in the presence of GVHD remains, suggesting that a combined approach will most likely be more effective.
Although fatal outcomes were exclusively observed in patients with GVHD not responding, it cannot be excluded that daclizumab may have contributed to the infectionrelated mortality. Results from a randomized study on first-line treatment of acute GVHD indicated an increased non-relapse mortality in the treatment arm containing daclizumab. 47 With regard to renal toxicity, the results demonstrate that calcineurin inhibitors can be replaced with daclizumab in the presence of RI leading to improvement, or at least stabilization, of renal function. However, two patients who developed RI as part of multiorgan failure owing to severe acute GVHD and associated infections did not appear to derive significant benefit except for the avoidance of hemodialysis. In patients with progressive renal failure due to long-term treatment with calcineurin inhibitors and/ or pre-existing renal impairment, daclizumab may offer the possibility of withdrawing the calcineurin inhibitor without exposing the patients to the risk of a flare of GVHD. Although two of three patients receiving daclizumab died later, it is unlikely that daclizumab contributed to their deaths, as these occurred in the presence of long-lasting severe chronic GVHD and months after daclizumab therapy.
In summary, the results demonstrate that daclizumab may effectively substitute calcineurin inhibitors in the treatment of TAM as well as RI in the presence of mild GVHD or remission of GVHD, leading to improvement of both TAM and renal function. In patients with concurrent active GVHD and TAM, mortality owing to GVHD and infectious complications remains high, and survival depends critically on control of both TAM and GVHD, warranting a more aggressive approach to the treatment of underlying GVHD (e.g. ATG).
